Pig kidney xenotransplantation
Transplanting genetically modified pig kidneys into humans.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 2, 3, 0, 0, 4.
All papers from the last 12 months
113 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Is the intraportal or renal subcapsular space a preferable site for islet allo- and xeno-transplantation? A brief historical reviewIslets2026 Dec 31PMID 42017902Review
- Xenotransplantation: The Next Surgical Revolution for Acute Liver Failure?Ann Surg2026 Nov 1PMID 42675556Review
- Inducible human yolk sac myeloid progenitors model myeloid ontogeny and enable tissue-resident macrophage replacement in vivoDev Cell2026 Oct 14PMID 42838060
- Bridging the gap: first-in-human pig kidney xenotransplantNat Rev Urol2026 Oct 5PMID 42834172
- From Gene Editing to Exogenesis: Pigs as a Source of Immune-compatible Organs for TransplantationTransplantation2026 Oct 1PMID 42547936Review
- Complement system in kidney transplantation: from innate immune surveillance to a therapeutic and genetic engineering targetFront Immunol2026PMID 42866368Review
- Multiomic analyses in xenotransplantation: Hypothesis generation and the path toward precision diagnostics: Vital Insights into XenotransplantationAm J Transplant2026 Sep 23PMID 42777950
- Spatial transcriptomic profiling of porcine tissue microarray detecting subclinical circovirus infectionFront Vet Sci2026PMID 42824453
- Kidney xenotransplantation-bridge to allotransplantation or destination treatment?Lancet2026 Sep 12PMID 42692039
- Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human studyLancet2026 Sep 12PMID 42692038
More nephrology trends
All specialties →Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Home dialysis
Home haemodialysis and peritoneal dialysis.
Key point: Core interventions to reduce PD-related infections focus on surveillance, standardized staff and patient training, infection prevention assessments, and antimicrobial prophylaxis.
HIF-PH inhibitors for anaemia
Oral drugs such as roxadustat for anaemia of kidney disease.
Key point: HIF-PHIs such as roxadustat are reserved for non-dialysis CKD when erythropoiesis-stimulating agents are unsuitable, given potential risks and limited long-term data.
Race-free eGFR
Kidney function equations without a race coefficient.
Potassium binders
Patiromer and sodium zirconium cyclosilicate for hyperkalaemia.
Key point: In type 2 diabetes with hyperkalemia, sodium zirconium cyclosilicate did not demonstrate noninferiority to potassium-restricted diet for achieving normokalemia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
xenotransplant*[tiab] AND (kidney[tiab] OR renal[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.